Personalis Inc is a biotechnology company that specializes in advanced genomics and personalized medicine. The firm focuses on providing comprehensive genomic profiling services to aid in the detection and treatment of cancer. Through its proprietary technologies, Personalis analyzes a patient's unique genetic makeup to deliver insights that support personalized therapeutic decisions and improve patient outcomes. The company's offerings are aimed at healthcare providers, researchers, and pharmaceutical companies seeking to leverage genomic data for better understanding and addressing complex diseases, particularly in oncology. Read More
Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the second quarter ended June 30, 2025, and recent accomplishments of its “Win-in-MRD” strategy:
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that the Compensation Committee of its Board of Directors granted, on July 15, 2025, a non-qualified stock option to purchase an aggregate of 100,000 shares of its common stock to Personalis’ new Vice President, Corporate Controller under Personalis’ 2020 Inducement Plan.
Jim Cramer advises against investing in Tempus AI due to its ongoing losses and suggests Pan American as a profitable alternative. Insmed is also considered speculative while the only viable option for autonomous vehicles is Tesla. Ouster's stock was downgraded and other companies experienced mixed price action.
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
Personalis, Inc. (Nasdaq: PSNL) today announced an expansion and extension of its strategic collaboration with Tempus AI, Inc. (Nasdaq: TEM), adding a new indication, colorectal cancer (CRC), to the existing, exclusive commercialization agreement. The update means Personalis and Tempus will now work to bring to market the NeXT Personal® ultra-sensitive, tumor-informed minimal residual disease (MRD) test to detect cancer recurrence in four areas: breast, lung and colorectal cancers, and solid tumor immunotherapy monitoring. The addition of CRC follows the presentation of compelling interim analysis results from the VICTORI study at the 2025 American Association for Cancer Research (AACR) Annual Meeting, which demonstrated strong performance of NeXT Personal for detecting early signs of residual or recurrent CRC.
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new results from the CALLA phase 3 study showing for the first time its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test detected cervical cancer progression, up to 16 months ahead of imaging. The results demonstrate the potential of NeXT Personal to enable earlier detection in a cancer with high recurrence rates.
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced the presentation of new clinical results from the PREDICT DNA and SCANDARE studies highlighting the capabilities of its ultrasensitive NeXT Personal circulating tumor DNA (ctDNA) blood test for monitoring and predicting neoadjuvant therapy (NAT) response in triple negative breast cancer (TNBC), one of the most aggressive types of breast cancer.
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced multiple presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting next week in Chicago, Illinois. The presentations feature new data from clinical studies utilizing the NeXT Personal® ultrasensitive ctDNA assay for residual and recurrent cancer detection.
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the Craig-Hallum 22nd Annual Investor Conference on Wednesday, May 28, 2025, at The Depot Renaissance Hotel in Minneapolis, MN.
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2025 ended March 31, 2025, and provided recent business highlights.
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced new interim analysis results of the VICTORI study showing strong performance of its ultra-sensitive NeXT Personal assay in detecting early signs of residual or recurrent colorectal cancer (CRC).
